Skip to main content

Table 1 Correlations of SPARC methylation with clinical characteristics of pancreatic cancer

From: Methylation of the SPARC gene promoter and its clinical implication in pancreatic cancer

Clinical characteristics

Cases (n = 40)

Methylation ratio (%)

  

Region 1

p

Region 2

p

Total

p

Gender

       

   Male

25

58.6 ± 11.8

0.709

53.6 ± 18.7

0.265

56.5 ± 11.9

0.337

   Female

15

59.8 ± 12.1

 

55.5 ± 22.6

 

58.0 ± 13.2

 

Age (yrs)

       

   ≤ 55

19

58.0 ± 12.0

0.386

52.6 ± 19.1

0.156

55.7 ± 12.1

0.142

   > 55

21

60.0 ± 11.7

 

56.0 ± 21.0

 

58.3 ± 12.6

 

Alcohol

       

   --

20

58.7 ± 12.9

0.794

46.6 ± 18.2

0.016

53.7 ± 11.2

0.154

   +

20

60.0 ± 11.7

 

62.1 ± 19.1

 

60.5 ± 12.6

 

Smoking

       

   --

22

58.1 ± 13.7

0.671

47.5 ± 17.5

0.017

53.7 ± 11.9

0.067

   +

18

60.2 ± 9.1

 

62.8 ± 19.1

 

61.3 ± 11.7

 

Tumor size (cm)

       

   ≤ 2

21

55.4 ± 10.5

0.087

46.1 ± 18.8

0.029

51.5 ± 10.1

0.013

   > 2

19

63.1 ± 12.0

 

63.5 ± 17.4

 

63.3 ± 11.7

 

Differentiation

       

   Moderate

19

59.6 ± 12.2

0.625

53.6 ± 20.4

0.799

57.1 ± 12.4

0.877

   Poor

21

58.6 ± 11.6

 

55.0 ± 20.1

 

57.1 ± 12.5

 

Lymph node metastasis

       

   --

23

60.4 ± 12.4

0.307

53.7 ± 20.0

0.832

57.6 ± 12.5

0.421

   +

17

57.2 ± 10.9

 

55.2 ± 20.7

 

56.4 ± 12.3

 

pTNM stage

       

   I+II

21

58.2 ± 12.4

0.444

51.9 ± 20.1

0.867

55.5 ± 12.6

0.543

   III+IV

19

60.0 ± 11.2

 

57.1 ± 20.0

 

58.8 ± 12.0

 
  1. Correlations of SPARC methylation with clinical characteristics of pancreatic cancer were determined by general linear model univariate analysis.